Parmax Pharma Ltd
Incorporated in 1994, Parmax Pharma Ltd manufactures Bulk Drugs, Drug Intermediates & Speciality Chemicals.[1]
- Market Cap ₹ 12.6 Cr.
- Current Price ₹ 33.6
- High / Low ₹ 55.0 / 28.0
- Stock P/E
- Book Value ₹ -12.9
- Dividend Yield 0.00 %
- ROCE -12.4 %
- ROE %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 30.5 to 16.6 days.
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 30.8%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 11.89 | 11.99 | 20.92 | 26.17 | 18.24 | 15.39 | 11.02 | 28.20 | 15.58 | |
| 0.02 | 0.02 | 0.05 | 0.05 | 10.81 | 10.88 | 19.15 | 22.74 | 15.67 | 13.14 | 14.39 | 27.94 | 17.87 | |
| Operating Profit | -0.02 | -0.02 | -0.05 | -0.05 | 1.08 | 1.11 | 1.77 | 3.43 | 2.57 | 2.25 | -3.37 | 0.26 | -2.29 |
| OPM % | 9.08% | 9.26% | 8.46% | 13.11% | 14.09% | 14.62% | -30.58% | 0.92% | -14.70% | ||||
| 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.10 | 0.09 | 0.06 | 0.04 | 0.05 | -1.03 | -1.14 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.13 | 0.37 | 0.39 | 0.37 | 0.62 | 0.59 | 0.87 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 1.09 | 1.03 | 1.01 | 1.94 | 1.93 | 1.88 | 1.71 | 1.03 | 0.73 |
| Profit before tax | 0.04 | 0.04 | 0.01 | 0.01 | 0.00 | 0.10 | 0.73 | 1.21 | 0.31 | 0.04 | -5.65 | -2.39 | -5.03 |
| Tax % | 0.00% | 25.00% | 200.00% | 100.00% | 20.00% | 41.10% | 38.02% | 54.84% | 375.00% | 1.77% | -12.55% | ||
| 0.04 | 0.02 | 0.00 | -0.01 | 0.00 | 0.08 | 0.43 | 0.75 | 0.14 | -0.10 | -5.75 | -2.09 | -4.72 | |
| EPS in Rs | 0.10 | 0.05 | 0.00 | -0.03 | 0.00 | 0.21 | 1.15 | 2.00 | 0.37 | -0.27 | -15.37 | -5.59 | -12.61 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 16% |
| TTM: | -31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -2% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.90 | 4.03 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 |
| Reserves | 0.09 | 0.12 | 0.11 | 0.10 | 0.11 | 0.18 | 0.61 | 1.37 | 1.51 | 1.40 | -4.35 | -6.44 | -9.28 |
| 0.92 | 0.79 | 0.46 | 1.02 | 1.96 | 5.52 | 5.26 | 5.89 | 5.18 | 5.37 | 5.91 | 7.71 | 11.51 | |
| 0.09 | 0.04 | 0.06 | 2.14 | 10.11 | 9.56 | 10.75 | 11.01 | 6.83 | 6.39 | 9.32 | 13.03 | 10.95 | |
| Total Liabilities | 5.00 | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 18.75 | 17.63 |
| 2.53 | 2.53 | 2.53 | 2.72 | 5.86 | 4.92 | 9.64 | 10.84 | 10.44 | 9.50 | 9.27 | 7.97 | 7.93 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.20 | 0.20 | 0.00 | 0.00 | 0.00 | 0.40 | 0.40 |
| 2.47 | 2.45 | 2.55 | 4.99 | 10.77 | 11.26 | 11.23 | 11.68 | 7.53 | 8.11 | 5.96 | 10.38 | 9.30 | |
| Total Assets | 5.00 | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 18.75 | 17.63 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.06 | 0.00 | -0.50 | 3.88 | 0.92 | 2.82 | 3.53 | 0.75 | 0.33 | -0.20 | -0.96 | |
| 0.00 | 0.00 | 0.00 | -0.19 | -4.23 | -3.41 | -2.40 | -3.15 | -1.53 | -0.94 | -1.59 | -0.70 | |
| 0.01 | 0.00 | 0.10 | 0.56 | 1.14 | 3.10 | -0.23 | 0.40 | -0.91 | -0.04 | 1.43 | 1.40 | |
| Net Cash Flow | 0.00 | -0.06 | 0.09 | -0.14 | 0.79 | 0.61 | 0.20 | 0.78 | -1.69 | -0.65 | -0.36 | -0.26 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 60.48 | 35.01 | 57.58 | 23.01 | 13.61 | 14.70 | 60.28 | 16.57 | ||||
| Inventory Days | 203.34 | 278.66 | 88.17 | 107.27 | 154.80 | 286.55 | 123.74 | 56.09 | ||||
| Days Payable | 609.39 | 645.07 | 311.84 | 269.40 | 299.82 | 309.82 | 382.60 | 173.18 | ||||
| Cash Conversion Cycle | -345.57 | -331.40 | -166.09 | -139.12 | -131.41 | -8.57 | -198.58 | -100.52 | ||||
| Working Capital Days | -59.86 | -71.84 | -56.18 | -48.26 | -36.02 | -0.47 | -115.59 | -40.38 | ||||
| ROCE % | 0.82% | 0.81% | 0.20% | 0.19% | 0.66% | 1.56% | 8.40% | 14.34% | 6.13% | 3.67% | -58.39% | -12.45% |
Documents
Announcements
- Results-Delay in Financial Results 17 Nov
-
Board Meeting Outcome for The Board Meeting Was Initially Rescheduled On November 15, 2025 And Thenafter On Today I.E. November 17, 2025 Hence Board Has Approved The Unaudited Financial Statements For Quarter And Half Year Ended On September 30, 2025
17 Nov - Board approved unaudited Q2/H1 results to Sep 30, 2025; limited review; insurance claim provision Rs.3.5 crore.
-
Board Meeting Intimation for Reschedule Of Board Meeting Supposed To Be Held On November 14, 2025
15 Nov - Board meeting rescheduled to November 15, 2025 to approve unaudited Q2 and H1 results for Sep 30, 2025.
-
Board Meeting Intimation for For Approval Of Unaudited Financial Results For Quarter Ended September 30, 2025
8 Nov - Board meeting on Nov 14, 2025 to approve unaudited Q2/H1 results ended Sep 30, 2025.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 29 Oct
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
Business Overview:[1]
PPL is engaged in the manufacture and supply
of bulk drugs (APIs) and selected formulations
catering primarily to the Indian pharma industry.